Valuation: Oncopeptides AB

Market Cap 832M 82.9M 73.7M 68.69M 62.61M 118M 7.98B 119M 323M 4.07B 311M 304M 13.19B P/E 2026 *
-4.43x
P/E 2027 * -9.36x
Enterprise Value 886M 88.27M 78.48M 73.15M 66.67M 126M 8.5B 127M 344M 4.34B 331M 324M 14.04B EV / Sales 2026 *
6.87x
EV / Sales 2027 * 3.58x
Free-Float
96.15%
Yield 2026 *
-
Yield 2027 * -
1 day-2.59%
1 week-15.76%
Current month-3.66%
1 month+11.13%
3 months+28.02%
6 months+50.43%
Current year-56.17%
1 week 2.11
Extreme 2.106
2.59
1 month 1.61
Extreme 1.612
2.64
Current year 1.26
Extreme 1.255
4.91
1 year 1.26
Extreme 1.255
6.55
3 years 1.1
Extreme 1.1
9.4
5 years 1.1
Extreme 1.1
50.84
10 years 1.1
Extreme 1.1
215
Manager TitleAgeSince
Chief Executive Officer 46 2023-08-06
Director of Finance/CFO 52 2023-11-12
Chief Tech/Sci/R&D Officer 54 2023-08-31
Director TitleAgeSince
Director/Board Member 65 2011-12-31
Director/Board Member 63 2017-01-31
Chairman 78 2018-05-16
Date Insider Type Main position Quantity % Market Cap. Importance
3/20/26 Free

Chief Technology Officer

3,000 0.0008%
3/18/26 Buy 14,631 0.0038%
3/17/26 Free

Investor Relations Manager

66 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-2.59%-15.76%-59.89%-74.50% 82.95M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -0.46%-2.11%+42.96%+100.80% 39.06B
Weighted average by Cap. +0.12%-0.84%+58.74%+129.86%

Financials

2026 *2027 *
Net sales 129M 12.84M 11.42M 10.64M 9.7M 18.31M 1.24B 18.48M 50.02M 631M 48.21M 47.17M 2.04B 252M 25.07M 22.29M 20.77M 18.93M 35.74M 2.41B 36.06M 97.63M 1.23B 94.11M 92.07M 3.99B
Net income -167M -16.58M -14.74M -13.74M -12.53M -23.64M -1.6B -23.86M -64.59M -815M -62.26M -60.91M -2.64B -62.47M -6.22M -5.53M -5.15M -4.7M -8.87M -599M -8.95M -24.23M -306M -23.35M -22.85M -990M
Net Debt 54M 5.38M 4.78M 4.46M 4.06M 7.67M 518M 7.74M 20.94M 264M 20.19M 19.75M 856M 68M 6.77M 6.02M 5.61M 5.11M 9.65M 652M 9.74M 26.37M 333M 25.42M 24.87M 1.08B
Logo Oncopeptides AB
Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
Employees
69
Date Price Change Volume
26-10-02 SEK 2.106 -2.59% 2,262,233
26-10-01 SEK 2.162 -1.10% 2,595,414
26-09-30 SEK 2.186 -3.02% 3,205,625
26-09-29 SEK 2.254 -5.69% 3,768,998
26-09-28 SEK 2.390 -4.40% 4,254,335
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
2.106SEK
Average target price
2.700SEK
Spread / Average Target
+28.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ONCO Stock